EA199700203A1 - Синергические комбинации зидовудина, 1592u89 и 3тс или ftc - Google Patents

Синергические комбинации зидовудина, 1592u89 и 3тс или ftc

Info

Publication number
EA199700203A1
EA199700203A1 EA199700203A EA199700203A EA199700203A1 EA 199700203 A1 EA199700203 A1 EA 199700203A1 EA 199700203 A EA199700203 A EA 199700203A EA 199700203 A EA199700203 A EA 199700203A EA 199700203 A1 EA199700203 A1 EA 199700203A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cis
amino
ftc
zidovudin
oxathiolan
Prior art date
Application number
EA199700203A
Other languages
English (en)
Other versions
EA000626B1 (ru
EA000626B3 (ru
Inventor
Дейвид Уолтер Бэрри
Марта Хайдер Сейнт-Клэр
Original Assignee
Де Веллкам Фаундейшн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199700203(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Application filed by Де Веллкам Фаундейшн Лимитед filed Critical Де Веллкам Фаундейшн Лимитед
Publication of EA199700203A1 publication Critical patent/EA199700203A1/ru
Publication of EA000626B1 publication Critical patent/EA000626B1/ru
Publication of EA000626B3 publication Critical patent/EA000626B3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение относится к терапевтической комбинации (1S,4R)-цис-4-[2-амино-6-(циклопропиламино)-9Н-пурин-9-ил]-2-циклопентен-1-метанола (1592U89), 3'-азидо-3'-деокситимидина (зидовудина) и (2R,цис)-4-амино-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1H)-пиримидин-2-она (ЗТС) (или, в качестве альтернативы для ЗТС, (2R,цис)-4-амино-5-фторо-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1Н)-пиримидин-2-она (FTC)), которая обладает ВИЧ-активностью. Настоящее изобретение также относится к фармацевтическим составам, содержащим упомянутые комбинации, и их применению для лечения ВИЧ-инфекций, включая инфекции мутантными ВИЧ, обладающими устойчивостью к нуклеозидным и/или ненуклеозидным ингибиторам.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199700203A 1995-03-30 1996-03-28 Синергические комбинации зидовудина, 1592u89 и зтс или ftc EA000626B3 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (3)

Publication Number Publication Date
EA199700203A1 true EA199700203A1 (ru) 1998-02-26
EA000626B1 EA000626B1 (ru) 1999-12-29
EA000626B3 EA000626B3 (ru) 2016-04-29

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700203A EA000626B3 (ru) 1995-03-30 1996-03-28 Синергические комбинации зидовудина, 1592u89 и зтс или ftc

Country Status (36)

Country Link
US (1) US6417191B1 (ru)
EP (1) EP0817637B1 (ru)
JP (1) JP2954357B2 (ru)
KR (1) KR100542536B1 (ru)
CN (1) CN1103593C (ru)
AP (1) AP652A (ru)
AT (1) ATE220551T1 (ru)
AU (1) AU715213B2 (ru)
BR (3) BR9607851B1 (ru)
CA (1) CA2216634C (ru)
CZ (1) CZ295940B6 (ru)
DE (3) DE122005000029I1 (ru)
DK (1) DK0817637T3 (ru)
EA (1) EA000626B3 (ru)
EE (1) EE04047B1 (ru)
ES (1) ES2179193T3 (ru)
FR (1) FR05C0022I2 (ru)
GE (1) GEP20022647B (ru)
HK (1) HK1009401A1 (ru)
HU (1) HU224010B1 (ru)
IL (1) IL117727A (ru)
LU (1) LU91171I2 (ru)
MX (1) MX9707316A (ru)
MY (1) MY115461A (ru)
NL (1) NL300195I2 (ru)
NO (2) NO313787B1 (ru)
NZ (1) NZ306419A (ru)
OA (1) OA10616A (ru)
PL (1) PL187085B1 (ru)
PT (1) PT817637E (ru)
RO (1) RO117995B1 (ru)
SI (1) SI0817637T1 (ru)
SK (1) SK283825B6 (ru)
TR (1) TR199701074T1 (ru)
UA (1) UA60293C2 (ru)
WO (1) WO1996030025A1 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ429498A3 (cs) * 1996-06-25 1999-06-16 Glaxo Group Limited Kombinace obsahující VX478, zidovudin, FTC a/nebo 3TC pro léčbu infekce HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
WO1998052570A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
CA2512319A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
AU2004224191A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
JP5415957B2 (ja) 2006-12-13 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
EP2982978A1 (en) 2009-05-27 2016-02-10 Immunaid Pty Ltd Methods of treating diseases
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
AU2015245217A1 (en) 2014-04-08 2016-10-13 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP4306524A2 (en) * 2017-08-29 2024-01-17 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
EP0513917B2 (en) * 1991-05-16 2001-03-07 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
DK0639971T3 (da) * 1992-05-13 2000-03-20 Wellcome Found Terapeutiske kombinationer
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ATE230267T1 (de) 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
CZ429498A3 (cs) 1996-06-25 1999-06-16 Glaxo Group Limited Kombinace obsahující VX478, zidovudin, FTC a/nebo 3TC pro léčbu infekce HIV
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
AU715213B2 (en) 2000-01-20
EE04047B1 (et) 2003-06-16
NO974510L (no) 1997-09-29
AU5497296A (en) 1996-10-16
BR9607851A (pt) 1998-07-21
IL117727A0 (en) 1996-07-23
BR9607851B1 (pt) 2009-01-13
CN1185110A (zh) 1998-06-17
LU91171I9 (ru) 2018-12-28
IL117727A (en) 1999-11-30
NL300195I2 (nl) 2005-11-01
CN1103593C (zh) 2003-03-26
BRPI9607851B8 (pt) 2019-11-05
DE122005000029I2 (de) 2006-04-27
CA2216634C (en) 2004-07-20
PL322532A1 (en) 1998-02-02
DE69622386T2 (de) 2003-02-13
FR05C0022I1 (ru) 2005-06-10
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
BRPI9612992B1 (pt) 2020-08-04
CZ295940B6 (cs) 2005-12-14
EA000626B1 (ru) 1999-12-29
CA2216634A1 (en) 1996-10-03
LU91171I2 (fr) 2005-07-04
NO313787B1 (no) 2002-12-02
NO2005014I2 (no) 2008-02-11
US6417191B1 (en) 2002-07-09
EP0817637B1 (en) 2002-07-17
KR100542536B1 (ko) 2006-03-23
DE122005000029I1 (de) 2005-10-06
RO117995B1 (ro) 2002-12-30
SK129597A3 (en) 1998-07-08
EA000626B3 (ru) 2016-04-29
MX9707316A (es) 1997-11-29
DE69622386D1 (de) 2002-08-22
NO2005014I1 (no) 2005-06-06
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
HK1009401A1 (en) 1999-09-10
JPH10511682A (ja) 1998-11-10
EP0817637A1 (en) 1998-01-14
FR05C0022I2 (ru) 2005-10-21
EE9700240A (et) 1998-04-15
HUP9801571A2 (hu) 1999-01-28
HUP9801571A3 (en) 2001-04-28
SI0817637T1 (en) 2002-10-31
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
UA60293C2 (ru) 2003-10-15
HU224010B1 (hu) 2005-04-28
NO974510D0 (no) 1997-09-29
AP652A (en) 1998-06-19
DK0817637T3 (da) 2002-11-11
PL187085B1 (pl) 2004-05-31
ES2179193T3 (es) 2003-01-16
KR19980703420A (ko) 1998-11-05
ATE220551T1 (de) 2002-08-15
CZ309097A3 (cs) 1998-05-13
JP2954357B2 (ja) 1999-09-27
OA10616A (en) 2001-03-15
MY115461A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
EA199700203A1 (ru) Синергические комбинации зидовудина, 1592u89 и 3тс или ftc
NO20053817L (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
YU74992A (sh) Postupak za pravljenje (-)4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
TW366346B (en) 1,3-oxathiolane nucleoside analogue
NO986034L (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
EA199900757A1 (ru) Фармацевтические композиции
AR009523A1 (es) Derivado de pirimidina 2,4-disustituida, procedimiento para preparar el mismo y una composicion farmaceutica que lo contiene.
AR023661A1 (es) Combinaciones antivirales
EA199801046A1 (ru) Комбинации, содержащие vx478, зидовудин и/или 1592u89, для применения при лечении вич
WO2001030329A3 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
AR043332A1 (es) Composiciones y metodos para terapia antiviral
NO995620L (no) Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89
WO2000018383A3 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
AR040805A1 (es) Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral
AR007616A1 (es) Combinaciones antivirales
ATE162401T1 (de) Antivitale zusammensetzungen

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent

Designated state(s): RU

PC4A Registration of transfer of a eurasian patent by assignment
LD4A Eurasian patent limited on request of patent holder (b3)
TK4A Corrections in published eurasian patents
ND4A Extension of term of a eurasian patent
MK4A Patent expired

Designated state(s): AM KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): AZ

MK4A Patent expired

Designated state(s): BY RU